Wednesday, February 22, 2023 9:09:28 AM
Recent WINT News
- Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong • GlobeNewswire Inc. • 11/04/2024 01:00:00 PM
- Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 • GlobeNewswire Inc. • 10/30/2024 12:00:00 PM
- Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World • GlobeNewswire Inc. • 10/23/2024 12:00:00 PM
- Windtree To Present at the ThinkEquity Conference on October 30th • GlobeNewswire Inc. • 10/21/2024 12:00:00 PM
- Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan • GlobeNewswire Inc. • 10/17/2024 12:15:00 PM
- Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design • GlobeNewswire Inc. • 10/09/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 11:46:52 AM
- Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/30/2024 12:15:00 PM
- Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET • GlobeNewswire Inc. • 09/26/2024 08:05:00 PM
- Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/25/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 12:05:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 09:21:14 PM
- Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/04/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/04/2024 04:15:11 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/03/2024 01:10:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/03/2024 01:09:25 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/03/2024 11:22:46 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 08/23/2024 08:15:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/21/2024 08:55:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:30:55 PM
- Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates • GlobeNewswire Inc. • 08/20/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 09:06:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:25 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM